Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 230

1.

Aspirin for primary prevention of cardiovascular disease events.

Nemerovski CW, Salinitri FD, Morbitzer KA, Moser LR.

Pharmacotherapy. 2012 Nov;32(11):1020-35. doi: 10.1002/phar.1127. Epub 2012 Sep 27. Review.

PMID:
23019080
2.

Aspirin for primary prevention: yes or no?

Selak V, Elley CR, Wells S, Rodgers A, Sharpe N.

J Prim Health Care. 2010 Jun;2(2):92-9.

PMID:
20690297
3.
4.

Update on aspirin in the treatment and prevention of cardiovascular disease.

Hennekens CH.

Am J Manag Care. 2002 Dec;8(22 Suppl):S691-700. Review.

5.

Aspirin for primary prevention of cardiovascular disease?

[No authors listed]

Drug Ther Bull. 2009 Nov;47(11):122-5. doi: 10.1136/dtb.2009.10.0045. Erratum in: Drug Ther Bull. 2010 Feb;48(2):24.

PMID:
19887685
6.
7.

The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.

Hennekens CH, Schneider WR.

Expert Rev Cardiovasc Ther. 2008 Jan;6(1):95-107. Review.

PMID:
18095910
8.

[Primary prevention with aspirin].

Divisón JA, Galgo A, Polo J, Durá R.

Semergen. 2012 Sep;38(6):366-76. doi: 10.1016/j.semerg.2012.01.006. Epub 2012 May 10. Spanish.

PMID:
22935833
9.

Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.

Morimoto T, Fukui T, Lee TH, Matsui K.

Am J Med. 2004 Oct 1;117(7):459-68. Review.

PMID:
15464702
10.

Aspirin in the treatment and prevention of cardiovascular disease.

Gaziano JM, Skerrett PJ, Buring JE.

Haemostasis. 2000;30 Suppl 3:1-13. Review.

PMID:
11182624
11.

Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials.

Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR.

Am Heart J. 2011 Jul;162(1):115-24.e2. doi: 10.1016/j.ahj.2011.04.006. Review.

PMID:
21742097
12.
13.

Assessing the risk/benefit profile before recommending aspirin for the primary prevention of cardiovascular events.

Rodondi N, Bauer DC.

Am J Med. 2004 Oct 1;117(7):528-30. Review. No abstract available.

PMID:
15464713
14.

Aspirin for the prevention of cardiovascular events in the elderly.

Mahé I, Leizorovicz A, Caulin C, Bergmann JF.

Drugs Aging. 2003;20(13):999-1010. Review.

PMID:
14561103
15.

Role of ASA in the primary and secondary prevention of cardiovascular events.

Casado-Arroyo R, Bayrak F, Sarkozy A, Chierchia GB, de Asmundis C, Brugada P.

Best Pract Res Clin Gastroenterol. 2012 Apr;26(2):113-23. doi: 10.1016/j.bpg.2012.01.013. Review.

PMID:
22542150
16.

Clinical use of aspirin in ischemic heart disease: past, present and future.

De Caterina R, Renda G.

Curr Pharm Des. 2012;18(33):5215-23. Review.

PMID:
22724410
17.

[Primary prevention of cardiovascular diseases with acetylsalicylic acid].

Waltering A, Hemkens L, Florack C.

Dtsch Med Wochenschr. 2005 Dec 9;130(49):2847-52. Review. German.

PMID:
16317615
18.

Aspirin for primary prevention of cardiovascular disease in women.

Jneid H.

Methodist Debakey Cardiovasc J. 2010 Nov-2011 Jan;6(4):37-42. Review.

PMID:
21088658
19.

Aspirin and primary cardiovascular prevention. Uncertain balance between benefits and risks.

[No authors listed]

Prescrire Int. 2010 Nov;19(110):258-61. Review.

PMID:
21284360
20.

Antiplatelet agents for the prevention of cardiovascular disease in diabetes mellitus.

Colwell JA.

Am J Cardiovasc Drugs. 2004;4(2):87-106. Review.

PMID:
15049721
Items per page

Supplemental Content

Write to the Help Desk